Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics (DNLI) has 6 years of Other Accumulated Expenses data on file, last reported at $4.4 million in Q4 2022.

• Quarterly Other Accumulated Expenses fell 91.75% year-over-year to $4.4 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $4.4 million (down 91.75% YoY) and the FY2022 annual result came in at $4.4 million, down 91.75% from the prior year.
• Other Accumulated Expenses retreated to $4.4 million in Q4 2022 per DNLI's latest filing, from $53.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $53.2 million in Q4 2021 and bottomed at $47000.0 in Q2 2018.
• The 5-year median for Other Accumulated Expenses is $3.5 million (2019), against an average of $14.1 million.
• The widest annual swing landed in 2018, when Other Accumulated Expenses jumped 30801.59%; it then plunged 91.75% in 2022.
• Tracing DNLI's Other Accumulated Expenses over 5 years: stood at $19.5 million in 2018, then gained by 23.36% to $24.0 million in 2019, then surged by 96.31% to $47.1 million in 2020, then gained by 12.77% to $53.2 million in 2021, then sank by 91.75% to $4.4 million in 2022.
• Per Business Quant, the three latest DNLI Other Accumulated Expenses figures stand at $4.4 million (Q4 2022), $53.2 million (Q4 2021), and $47.1 million (Q4 2020).

Peer Comparison